Leukapheresis Market Size & Share, by Product Type (Leukapheresis Columns & Cell Separators, Leukapheresis Disposables, Apheresis Devices, Leukoreduction Filters); Application (Therapeutic, Research); End-user (Blood Component Provider, Blood Center, Hospitals) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5887
  • Published Date: Mar 19, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Leukapheresis Market size is anticipated to reach USD 8 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of leukapheresis was USD 1 Billion. The demand for leukapheresis is driven by an increasing incidence of leukemia, as leukapheresis is a critical medical procedure to trealeukemia. As per a report, in 2023, there will be 1,958,310 new cancer cases diagnosed in the US; of these, leukemia, lymphoma, and myeloma cases are predicted to make up 9.4%. Leukapheresis is a procedure to remove white blood cells that may be used for other medical purposes, such as stem cell transplantation and immunotherapy. The need for leukapheresis to support these treatments is increasing as the incidence of leukemia increases, and this has led to an increase in sales.

Leukapheresis can be performed to harvest stem cells from children for other cancer patients as well as to treat or eliminate excess WBCs in children with lymphoma. Leukapheresis is a market focus because of its potential and advantages in this application, particularly as children's leukapheresis treatment is now only available in a small number of hospitals in developed and developing nations. Therefore, this factor is propelling the growth of the leukapheresis market.


Leukapheresis Market
Get more information on this report: Request Free Sample PDF

Leukapheresis Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Demand for Leukopaks in Clinical Research - Increased demand for leukopaks is also due to the growing interest in clinical trials involving immunotherapies and other cell-based treatments. Leukopads are comprised of a single selection of white blood cells essential for many types of medical research, including immunology, drug development, and cellular therapy. In addition, the leukapheresis market growth is being driven by an increasing number of advanced leukopaks launched for R&D activities. For instance, The Microbubble Leukopak Human T Cell Isolation research-use-only kit from Akadeum Life Sciences, Inc., a leader in buoyancy-based cell separation technology worldwide, has been released. This product is the outcome of successful external user data collected from early adopters.
  • Growing Cases of Blood-related Disorders - The growth of the leukapheresis market is being driven by a growing number of patients with blood-related disorders. In the treatment of various blood leukemic disorders such as leukemia, lymphoma, and myeloma, apheresis is an important procedure. For instance, in 2020, there were 176,404 new cases of multiple myeloma diagnosed globally.  Leukapheresis assists in the management of disease symptoms, reducing complications and improving patients' outcomes by selective removal of certain blood components. The development of new treatments and approaches is also driven by the increasing knowledge of blood-related disorders, as well as advances in medical research. Consequently, demand for leukapheresis procedures is growing as the incidence of blood disorders increases.
  • Increasing Clinical Trials for CAR T-cell Therapy - CAR T-cell therapy is a rapidly evolving field, with ongoing research aimed at optimizing treatment efficacy, expanding indications, and reducing side effects. For instance, in preclinical trials, a novel form of CAR T-cell therapy that was developed by researchers at a University specifically targeted cancer cells while preserving healthy cells. This could potentially lower the risk of harmful side effects from this ground-breaking cancer treatment. The cancer of the plasma cells located in the bone marrow of the body, known as multiple myeloma, was the reason behind the creation of the cells. Therefore, the increasing incidences of cancer, particularly hematologic malignancies such as leukemia and lymphoma, fuel the demand for innovative treatment options like CAR T-cell therapy.

Challenges

  • High Costs of the Procedures - Because leukapheresis treatments and related products can be costly, patients and healthcare facilities may not be able to obtain them, especially in areas with poor financial resources or insufficient healthcare infrastructure. Therefore, the high costs of the products may hinder the growth of the leukapheresis market.
  • Lack of Skilled Technical professionals may Hamper the Growth of the Market
  • Blood Transfusion Safety in Developing Countries may Hinder leukapheresis market Growth

Leukapheresis Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~ 6%

Base Year Market Size (2023)

 ~ USD 1 Billion

Forecast Year Market Size (2036)

 ~ USD 8 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Leukapheresis Segmentation

Product Type (Leukapheresis Columns & Cell Separators, Leukapheresis Disposables, Apheresis Devices, Leukoreduction Filters)

Leukapheresis disposables segment in the leukapheresis market is expected to hold a share of 46% during the forecast period. The demand for leukapheresis disposables is also increasing due to the increasing incidence of diseases such as leukemia, lymphoma, and autoimmune diseases. For instance, some of the more than 80 distinct autoimmune illnesses that impact about 4% of the global population are type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn's disease, psoriasis, and scleroderma. The disposables used in leukapheresis operations include items for entering blood vessels, storing blood components, and preventing blood clotting with anticoagulants. Both therapeutic leukapheresis and automated blood collection employ disposables. They consist of a variety of solutions such as saline, anticoagulants, media, columns, filters, and cell separation kits, as well as apheresis catheters, needle sets, centrifuge bowls, tubing sets/pipeline systems, and collection bags. In addition, due to their convenience, cost-effectiveness, and reduced risk of cross-contamination, there is a growing trend toward the adoption of single-use technologies in healthcare settings. Therefore, the growth of this segment is being driven by these factors.

Application (Therapeutic, Research)

Therapeutic segment in the leukapheresis market is anticipated to hold the largest share of 54% during the forecast period. Leukapheresis, including leukemia, lymphoma, and myeloma, is a key therapeutic intervention for the management of many blood disorders. In addition, leukapheresis is an integral part of stem cell transplantation, which is a cure for certain hematologic malignancies and genetic disorders. In addition, leukapheresis helps to reduce excessive immune responses, reduce inflammation, and reduce symptoms of the disease by removing pathogenic immune cells or inflammatory mediators from circulation. In addition, new therapeutic solutions for leukapheresis beyond traditional indications are being explored in ongoing research and clinical studies. These include leukapheresis for the treatment of sepsis, acute respiratory distress syndrome, and some neurological disorders. Therefore, these factors are contributing to the growth of therapeutic segment.

Our in-depth analysis of the global market includes the following segments:

     Product Type

  • Leukapheresis Columns & Cell Separators
  • Leukapheresis Disposables
  • Apheresis Devices
  • Leukoreduction Filters

     Application

  • Therapeutic
  • Research

     End-user

  • Blood Component Provider
  • Blood Center
  • Hospitals

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Leukapheresis Industry - Regional Synopsis

North American Market Forecast

North American leukapheresis market is poised to hold the largest share of 36% during the forecast period. The primary drivers of the current leukapheresis industry are an increase in neurological illnesses and blood-related disorders like "leukemia," which are already extremely frequent and common in this region. Additionally, the region is home to highly qualified medical personnel and well-equipped facilities. Furthermore, the region sets the standard for the use of cell-based treatments including stem cells and CAR T-cell therapy. For instance, in December 2021, T-ChargeTM, Novartis's next-generation CAR-T platform, was unveiled. It will act as the basis for several novel investigational CAR-T cell therapies that the company has in the works. The leukapheresis market expanded as a result of the region's increasing need for cell-based therapies.

European Market Statistics

Leukapheresis market in Europe is expected to grow with a share of 28% by the end of 2036. The rising incidence of blood disorders is one of the key factors expanding the market in the region. Also, the growth can be attributed to the growing investment in the healthcare sector. For instance, 2018 saw USD 1.95 billion financed by Europe in research and innovation through 1.708 initiatives in 20 Member States. The top three countries with the largest financing shares are Spain, Hungary, and Poland. Furthermore, Europe is a center for immunotherapy, cancer, and hematology clinical research and innovation. Leading academic institutions and pharmaceutical businesses are present, which promotes innovation and expands the leukapheresis market.

Research Nester
Leukapheresis Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Leukapheresis Landscape

top-features-companies
    • BioLineRx Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Gilead Sciences, Inc.
    • Haemonetics Corporation
    • Charles River Laboratories
    • Fresenius SE & Co.
    • StemExpress, LLC
    • AllCells, LLC
    • Cerus Corporation
    • Hemacare Corporation
    • Macopharma SA.

In-the-news

In The News

  • The U.S. Food and Drug Administration (FDA) has approved APHEXDATM (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. BioLineRx Ltd., a commercial-stage biopharmaceutical company focused on certain cancers and rare diseases. Subcutaneous usage of APHEXDA is achieved through injectable administration.
  • Kite, a Gilead Company (Nasdaq: GILD), announced that the FDA in the United States authorized a modification to the manufacturing process that will shorten the manufacturing time for Yescarta® (axicabtagene ciloleucel). It is estimated that Kite's median turnaround time (TAT) in the United States will drop from 16 days to 14 days with this approval. The time interval between leukapheresis, the collection of a patient's T cells, and product release is known as the median TAT. Manufacturing is a crucial phase in this process that gets a patient's cells ready for a unique one-time cell therapy injection.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5887
  • Published Date: Mar 19, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing demand for leukopaks in clinical research, growing cases of blood-related disorders, and increasing clinical trials for CAR T-cell Therapy are the major factors driving the growth of the leukapheresis market.

The market size of leukapheresis is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024 -2036.

The major players in the market are BioLineRx Ltd., Gilead Sciences, Inc., Haemonetics Corporation, Charles River Laboratories, Fresenius SE & Co., StemExpress, LLC, AllCells, LLC, Cerus Corporation, Hemacare Corporation, Macopharma SA., and others.

The therapeutic segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Leukapheresis Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying